Kentucky Trust Co Acquires Shares of 825 Solventum Co. (NYSE:SOLV)

Kentucky Trust Co acquired a new stake in Solventum Co. (NYSE:SOLV) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 825 shares of the company’s stock, valued at approximately $54,000.

A number of other institutional investors have also recently bought and sold shares of the business. Stonebridge Financial Group LLC bought a new stake in Solventum in the 4th quarter valued at about $26,000. Savant Capital LLC lifted its holdings in shares of Solventum by 6.3% during the 4th quarter. Savant Capital LLC now owns 3,914 shares of the company’s stock worth $259,000 after acquiring an additional 233 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Solventum by 2.0% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 13,677 shares of the company’s stock worth $904,000 after acquiring an additional 264 shares during the period. Strategic Financial Concepts LLC bought a new stake in shares of Solventum during the 4th quarter worth approximately $990,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Solventum by 55.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,791 shares of the company’s stock worth $3,959,000 after acquiring an additional 21,362 shares during the period.

Solventum Price Performance

SOLV stock opened at $73.62 on Thursday. The company has a 50 day simple moving average of $70.51 and a 200 day simple moving average of $68.32. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SOLV. Piper Sandler upped their price target on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Morgan Stanley upped their price target on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Mizuho began coverage on shares of Solventum in a report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price target for the company. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.